

The Era of Exponential Improvement in Healthcare?

CONV2X

October 2019

Any further distribution or use of the document
requires written permission from McKinsey

CONFIDENTIAL AND PROPRIETARY

Any use of this material without specific permission of McKinsey & Company
is strictly prohibited



1 Technology advances affecting profit pools today

2 Healthcare focus of the “big three” tech giants


3 Strategic implications for incumbents

1 Profit pools are shifting across the US healthcare industry, with varying growth rates by sector

Projected changes in EBITDA across US healthcare industry
2020, \$B

2016-2020 Growth rates

Percentage of EBITDA growth: ■ <5% ■ 5-10% ■ >10%




Health insurers

Delivery system

Service vendors

Manufacturers & Distributors

1 Emerging information and medical technologies are reshaping healthcare...




1 Tech profit pools are growing >10% around analytics and consumer engagement, suggesting the greater importance of these capabilities

Projected changes in EBITDA across US healthcare industry for tech and services 2021, \$B

EBITDA CAGR (2016-2021)

Percentage of EBITDA growth: ■ <5% ■ 5-10% ■ >10%



SOURCE: The evolving healthcare technology and services market – and why it matters; McKinsey & Co; <https://healthcare.mckinsey.com/evolving-healthcare-technology-and-services-market%E2%80%94and-why-it-matters>

2 | Leading tech players have increasingly distinctive value propositions to offer healthcare stakeholders



Distribution ecosystem

Smart devices ecosystem

AI-facilitated clinical ecosystem

Core value proposition

- Offers customer-centric, premier **logistics** where consumers can “*find and discover anything they might want to buy online*”
- Creates sleek and intuitive **devices** that may provide healthcare consumers with increased autonomy, informed by fully-integrated and longitudinal data sets
- “**Organizes the world’s information**” to better understand the health consumer and their environment

Example partnerships

- Pill Pack
- Berkshire Hathaway
- JPMorgan Chase
- Fred Hutchinson Cancer Research Center
- Duke
- Stanford
- Cerner
- AliveCor
- Gliimpse
- Verily
- DeepMind
- Galvani bioelectronics

Example developing capabilities

- Pharmacy, prescription management, and delivery infrastructure (PillPack)
- Joint venture and resources to improve employee healthcare (JPMorgan and Berkshire Hathaway)
- Clinical partner to support cancer-focused machine learning research (Fred Hutchinson Cancer Center)
- Longitudinal health record system through partnerships with EHR vendors (e.g., Cerner) and hospital organizations (e.g., Duke, Stanford)
- FDA-approved medical accessories to wearable products (AliveCor’s EKG reader)
- Platform to enable user collection and personalization of data (Gliimpse)
- New partners for AI-healthcare applications (Verily)
- Artificial intelligence research expertise and partnership with healthcare systems (DeepMind)
- Bioelectric medicine expertise to treat chronic disease using miniature electronic implants (Galvani)

SOURCES: <https://www.aboutamazon.com/>; <http://phx.corporate-ir.net/phoenix.zhtml?c=176060&p=irol-newsArticle&ID=2356401>; <https://www.cnbc.com/2018/07/30/jamie-dimon-says-health-care-initiative-with-buffett-and-bezos-may-sta.html>; <https://www.fredhutch.org/en/news/releases/2018/08/fred-hutch-techcompaniesteamupwithobliteride.html>; <https://www.apple.com/healthcare/>; <https://support.apple.com/en-us/HT208647>; <https://www.alivecor.com/>; <https://www.wsj.com/articles/apple-purchases-medical-startup-gliimpse-1471891422>; <https://verily.com/projects/>; <https://deepmind.com/applied/deepmind-google/>; <https://us.gsk.com/en-us/media/press-releases/2016/gsk-and-verily-to-establish-galvani-bioelectronics-a-new-company-dedicated-to-the-development-of-bioelectronic-medicines/>

3 We see four major disruptions possible in healthcare – today, we will focus the potential for new healthcare ecosystems

Details follow



1 New healthcare ecosystems



2 Radically more efficient medical supply chain




3 Modernized transaction and data infrastructure



4 Faster, more effective therapy development

3 What has not yet been created is an end-to-end, fully-integrated data infrastructure, delivering new ecosystems of care via artificial intelligence




3 | Tech giants – or healthcare incumbents – could design new ecosystems of care tailored to unique populations



A. Healthy or well-managed chronic



B. High needs and multiple comorbidities



C. Specialty chronic conditions (e.g., cancer)

**Estimated lives
By 2025**

~200-250M

~50-60M

~25-35M

**Estimated spend
By 2025**

~\$250-350B


~\$800-900B¹

~\$700-900B

¹ Does not include spending on areas that may take more time for technology to develop value-creating solutions, such as unplanned acute medical episodes, certain planned acute procedures, severe disabilities care, long-term care spend, or end-of-life care

SOURCE: Medical Expenditure Panel Survey; National Health Expenditure Accounts estimates, CMS

Technology-driven value is based upon a set of potential use cases



3 | Key questions for incumbents



Level of urgency

Are changes evolutionary or revolutionary?



Engagement with tech companies

Are they friends to partner with or foes to compete with?



Leveraging strengths

How can incumbents make themselves indispensable (e.g., via local market density or brand)?